Clinical Policy: Facility-based Sleep Studies for Obstructive Sleep Apnea

Reference Number: CP.MP.248
Date of Last Revision: 08/23

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Polysomnography (PSG) is the continuous and concurrent monitoring and recording of various physiological and pathophysiological parameters of sleep that includes physician evaluation, interpretation and dissemination. PSG is performed to diagnose various sleep disorders and evaluate the response to treatments such as continuous positive airway pressure (CPAP). This policy establishes the medical necessity requirements for facility-based polysomnography (PSG), split-night studies, and bi-level and continuous positive airway pressure (CPAP/BiPAP) titration for suspected obstructive sleep apnea.

Policy/Criteria
I. It is the policy of health plans affiliated with Centene Corporation® that initial polysomnography (PSG) or a split-night study in a facility for evaluation of obstructive sleep apnea for members/enrollees ≥ 18 years of age is medically necessary when meeting all of the following criteria:
A. Member/enrollee has suspected obstructive sleep apnea;
B. Portable or home sleep apnea testing (HSAT) is not appropriate due to one or more of the following:
   1. Portable/HSAT services are not available;
   2. Member/enrollee is unable to properly operate or tolerate home study equipment and another individual is not available to assist;
   3. Previous HSAT results are negative or inadequate for diagnosis and/or autotitration of positive airway pressure (APAP) for suspected obstructive sleep apnea;
   4. Chronic opioid use;
   5. Low pretest probability of OSA (normal BMI (<30), normal airway (Mallampati score 1 to 2), no snoring, and normal neck circumference (less than 17 inches in biological males, and less than 16 inches in biological females)). Note: HSAT has a lower sensitivity for detection of OSA, making a facility PSG more appropriate in the presence of a low pretest probability of OSA;
   6. Member/enrollee works in a mission-critical function and falling asleep at work would have a major negative impact (e.g. airline pilots, bus drivers, taxi drivers, ride-sharing drivers, truck drivers, train operators, police, security, military posts, astronauts);
   7. Member/enrollee has a BMI of ≥ 50 kg/m²;
   8. Both of the following:
      a. Member/enrollee has one or more of the following risk factors:
         i. Clinically significant chronic obstructive pulmonary disease or other chronic lung disease as evidenced by any of the following:
            a) Continuous, chronic nocturnal oxygen use;
            b) Moderate to severe pulmonary function impairment;
ii. Moderate to severe congestive heart failure as evidenced by one or more of the following:
   a) Documented pulmonary congestion with associated limiting dyspnea symptoms;
   b) New York Heart Association (NYHA) class III or IV heart failure. Note: See Table 1 below for NYHA classifications;
iii. History of ventricular fibrillation or sustained ventricular tachycardia in the absence of an implanted defibrillator;
iv. Neurologic or neuromuscular disease (e.g., stroke with significant residual effects, epilepsy, Parkinson’s disease, spina bifida, myotonic dystrophy, amyotrophic lateral sclerosis);
v. Complex sleep disorder, suspected (e.g., narcolepsy, parasomnia, cataplexy, periodic limb movement disorder);

b. Member/enrollee has signs or symptoms suggestive of moderate- to high- risk obstructive sleep apnea as evidenced by one or more of the following:
i. Epworth Sleepiness Scale score of 10 or greater;
ii. Excessive daytime sleepiness, fatigue, or awakening with gasping or choking, and one of the following:
   a) High risk for injury (e.g., falling asleep while driving);
   b) Member/enrollee has a BMI > 30 kg/m²;
   c) Refractory hypertension and medication regimen includes three or more antihypertensive drugs at therapeutic dosages, including one diuretic, and office blood pressure remains above goal;
iii. Observed apnea or choking episodes;
iv. Significant oxygen desaturation (i.e., less than 88%) on overnight pulse oximetry.

II. It is the policy of health plans affiliated with Centene Corporation that repeat facility-based polysomnography (PSG) or split-night study (after an initial PSG or split-night study) for evaluation of obstructive sleep apnea for members/enrollees ≥ 18 years of age is medically necessary when meeting all of the following:
A. All of the criteria in section I.B are met;
B. The requested study and any previous studies amount to two or less per rolling year;
C. Any of the following:
   1. Oral appliance has been adjusted for fit and requires assessment of efficacy;
   2. A change of device is needed due to intolerance of current device;
   3. Assessment of whether positive airway pressure (PAP) treatment settings need to be changed (including but not limited to continued symptoms despite adherent use: at least four hours/night for 70% of nights over a 30-day period);
   4. Significant weight loss (>10%) in a member/enrollee using PAP to determine if it can be discontinued;
   5. Member/enrollee has had significant weight gain or recurrent symptoms and a repeat study will help inform whether PAP should be reinstituted;
   6. Postoperative assessment of efficacy of surgery to treat OSA after upper airway surgical procedures;
7. Remote history of OSA and not on PAP with a need to re-establish diagnosis and/or initiate CPAP;
8. Suspicion of obstructive sleep apnea due to new signs or symptoms (e.g., weight gain accompanied by symptoms, new nocturia) in member/enrollee with previous negative study;
9. Signs, symptoms and strong clinical suspicion of OSA in member/enrollee with a negative study at least six months previous.

III. It is the policy of health plans affiliated with Centene Corporation that facility-based titration of CPAP/BiPAP for evaluation of OSA for members/enrollees ≥ 18 years of age is **medically necessary** when meeting one of the following:
A. Approved for a facility-based PSG and has not attempted a home-based study for titration of APAP;
B. Diagnosed with OSA during HSAT and there is evidence or documentation of failure of an APAP trial including, but not limited to, downloaded compliance data;
C. Diagnosed with central sleep apnea during HSAT and any of the following:
   1. Five or more central apnea events and/or central hypopnea events per hour of sleep;
   2. Central hypopnea events constitute > 50% of the total number of apnea and hypopnea events;
D. Diagnosed with treatment-emergent central sleep apnea (i.e., CPAP treatment led to emergency of central events) based on HSAT, the apnea was not resolved by an adequate trial of CPAP therapy, and one of the following:
   1. Five or more central apnea events and/or central hypopnea events per hour of sleep;
   2. Central hypopnea constitutes > 50% of the total number of apneas and hypopneas.

IV. It is the policy of health plans affiliated with Centene Corporation that there is insufficient evidence to support the use of actigraphy testing alone for diagnosis of obstructive sleep apnea as its effectiveness has not been established.

<table>
<thead>
<tr>
<th>Classification</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class I</strong></td>
<td>Patients with cardiac disease but without the resulting limitations in physical activity. Ordinary activity does not cause undue fatigue, palpititation, dyspnea, or anginal pain</td>
</tr>
<tr>
<td><strong>Class II</strong></td>
<td>Patients with heart disease resulting in slight limitations of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpititation, dyspnea or anginal pain</td>
</tr>
<tr>
<td><strong>Class III</strong></td>
<td>Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation, dyspnea, or anginal pain.</td>
</tr>
<tr>
<td><strong>Class IV</strong></td>
<td>Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. They symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort increases.</td>
</tr>
</tbody>
</table>
Background
Sleep-disordered breathing consists of several distinct disorders including obstructive sleep apnea (OSA), central sleep apnea (CSA), both with and without Cheyne-Stokes respiration, and sleep-related hypoventilation and hypoxemia. Sleep apnea, a serious and potentially dangerous sleep disorder in which breathing repeatedly stops and starts, is divided into two main types, OSA and CSA. The most common form of sleep apnea, OSA, is characterized by the partial or complete collapse of the upper airway during sleep, which causes symptoms such as excessive daytime sleepiness, gasping, snorting, loud snoring, and interrupted breathing.

The International Classification of Sleep Disorders defines OSA as five or more predominantly obstructive respiratory events per hour in the presence of symptoms or certain comorbidities; or by 15 or more predominantly obstructive respiratory events per hour in asymptomatic patients. Global estimates suggest that 936 million people between the ages of 30 and 69 years old have been diagnosed with mild to severe OSA and 425 million people with moderate to severe OSA.

A detailed sleep history and examination accompanied by validated screening tools such as the Epworth Sleepiness Scale or STOP-Bang questionnaire, assist with the identification of patients with sleep-disordered breathing. However, sleep testing is necessary for diagnostic confirmation.

OSA should be suspected when a patient presents with excessive daytime sleepiness, snoring and choking, or gasping during sleep, especially in the presence of high-risk factors like advanced age and obesity, and in those with a male reproductive system. Additional complications related to OSA include refractory hypertension, atrial fibrillation, nocturnal angina, dysrhythmias, congestive heart failure, stroke, and transient ischemic attacks.

Polysomnography (PSG) is a comprehensive sleep study that monitors several physiologic components relevant to the assessment of sleep-disordered breathing such as sleep stage, respiratory flow, respiratory effort, pulse oximetry and ventilation. PSG results are interpreted by the reviewing clinician and treatment recommendations are made based on the recorded signals, results of scoring, and clinical history. PSG tests can be used as a part of the diagnosis of a variety of additional sleep disorders including sleep-related movement disorders, narcolepsy, and certain parasomnias. They are also used for titration of positive airway pressure and to assess the adequacy of ongoing therapy.

PSG is conducted as a full-night study or split night study. A full night study involves monitoring the patient overnight, and if OSA is diagnosed, a return to the facility for PAP titration is sometimes necessary. A split-study involves monitoring of the patient’s sleep pattern for the first part of the night, and if OSA is diagnosed, PAP titration is initiated the second part of the night.

Home sleep apnea testing (HSAT) may be an appropriate, less stressful option for select patients with a high pretest probability of moderate to severe uncomplicated OSA, provided there is no suspicion of non respiratory sleep disorders (e.g., narcolepsy, severe insomnia, parasomnias, movement disorders); no significant cardiorespiratory disease (e.g., COPD, asthma, CHF); they
are not a mission-critical worker (e.g., airline pilot, bus driver, truck driver, astronaut); and a sleep expert is available to interpret the results.\textsuperscript{4,12,15,16,17}

The most common HSAT devices currently used are classified as sleep monitoring devices of type 3 and type 4. Type 3 is preferred to type 4 because of the additional number of variables measured—four to seven versus one to three variables. The AASM considers home monitoring devices adequate when a minimum of the following sensors are included: nasal pressure, chest and abdominal respiratory inductance plethysmography, oximetry, or peripheral artery tone (PAT), actigraphy, oximetry.\textsuperscript{4,11,18}

Studies have demonstrated the validity of HSAT results when compared to facility-based PSG. They note high sensitivity and specificity in populations at high risk of moderate to severe OSA based on clinical symptoms and in the absence of significant comorbidities that affect sleep or non respiratory sleep disorders.\textsuperscript{4,11,18}

Advantages of HSAT include the convenience of testing at home and cost effectiveness.\textsuperscript{11} The primary disadvantage of HSAT is that fewer physiologic variables are measured when compared with facility-based PSG, which can increase the likelihood for false-negative results. For most patients with suspected mild OSA, facility-based PSG is preferred since HSAT may lead to the under detection of sleep-related events in this population.\textsuperscript{4,11}

Coding Implications
This clinical policy references Current Procedural Terminology (CPT\textsuperscript{®}). CPT\textsuperscript{®} is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2021, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT codes that support coverage

<table>
<thead>
<tr>
<th>CPT\textsuperscript{®} Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>95807</td>
<td>Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, attended by a technologist</td>
</tr>
<tr>
<td>95808</td>
<td>Polysomnography; any age, sleep staging with 1-3 additional parameters of sleep, attended by a technologist</td>
</tr>
<tr>
<td>95810</td>
<td>Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist</td>
</tr>
<tr>
<td>95811</td>
<td>Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist</td>
</tr>
</tbody>
</table>

CPT codes that do not support coverage
CPT® Codes | Description
--- | ---
95803 | Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording)

Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Description</th>
<th>Revision Date</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy developed. Specialist reviewed.</td>
<td>01/23</td>
<td>01/23</td>
</tr>
<tr>
<td>Edited revision log entry from 1/23 to state “specialist reviewed” instead of “internal specialist reviewed.” Changed title to “Facility-Based Sleep Studies for Obstructive Sleep Apnea.” Updated description to include facility-based PSG, split-night studies and titration. Changed “sleep center” studies to “facility-based” studies throughout policy. Expanded scope of policy statement I. to include split-night studies. Clarified in I.B.3. that the titration was APAP. In I.B.5, added note about decreased sensitivity of HSAT in the presence of low probability of OSA. Added I.B.6. and I.B.7. as factors indicating that facility testing: mission-critical workers and BMI &gt;50. Removed indication in I.B. for sleep center PSG performed simultaneously with CPAP titration in split-night study as the criteria now applies to split-night studies. Specified in I.B.8.a.i.a)1) that the nocturnal oxygen use is chronic and continuous. In I.B.8.a.ii.a), specified that pulmonary congestion has associated limiting dyspnea symptoms. In I.B.8.a.ii.b), removed option for left ventricular EF and instead referred to NYHA heart failure classification table. In I.B.8.a.iv., specified that the residual effects from stroke must be significant. In I.B.8.a.v., added parasomnia as an example of a complex sleep disorder. In B.8.b.ii.c), changed “resistant hypertension” to “refractory hypertension.” In B.8.b.v., changed desaturation value to 88% from 90%. Added criteria sections II. and III. for repeat facility-based PSG/split-night studies and facility-based titration. Added code 95811.</td>
<td>03/23</td>
<td>03/23</td>
</tr>
<tr>
<td>Revised criteria III.B. by removing requirement to meet criteria for facility-based sleep study and rewording failed APAP trial statement.</td>
<td>06/23</td>
<td>06/23</td>
</tr>
<tr>
<td>Corrected I.B.8.a.i. to require either continuous, chronic nocturnal oxygen use or moderate to severe pulmonary function impairment instead of both.</td>
<td>08/23</td>
<td>08/23</td>
</tr>
</tbody>
</table>

References


10. Tam W, Ng SS, To KW, Ko FW, Hui DS. The interaction between hypertension and obstructive sleep apnea on subjective daytime sleepiness. *J Clin Hypertens (Greenwich)*. 2019;21(3):390 to 396. doi:10.1111/jch.13485


**Important Reminder**
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.
This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

**Note: For Medicaid members/enrollees**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

**Note: For Medicare members/enrollees**, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at [http://www.cms.gov](http://www.cms.gov) for additional information.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.